MEI Pharma, Inc. (MEIP)

MEI Pharma Income Statement

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021	Jun 30, 2020
Revenue	-	65.3	48.82	40.7	34.8	27.76
Revenue Growth (YoY)	-	33.76%	19.95%	16.96%	25.36%	464.72%
Cost of Revenue	5.59	15.97	48.93	-	1.41	2.67
Gross Profit	-5.59	49.33	-0.11	40.7	33.39	25.09
Selling, General & Admin	11.16	22.98	32.33	30.54	24.41	16.72
Research & Development	0.35	0.35	0.72	85.64	69.4	34.07
Operating Expenses	11.51	23.33	33.05	116.18	93.81	50.78
Operating Income	-17.1	26	-33.16	-75.48	-60.42	-25.7
Interest & Investment Income	1.44	3.28	3.35	0.28	0.51	1.4
Other Non Operating Income (Expenses)	-0.05	-0.04	1.58	20.75	18.61	-22.87
EBT Excluding Unusual Items	-15.71	29.23	-28.24	-54.45	-41.31	-47.17
Merger & Restructuring Charges	-5.56	-0.56	-3.6	-	-	-
Asset Writedown	-10.9	-10.9	-	-	-	-
Pretax Income	-31.66	17.78	-31.84	-54.45	-41.31	-47.17
Income Tax Expense	-	-	-	-	0.01	0
Net Income	-31.66	17.78	-31.84	-54.45	-41.31	-47.17
Net Income to Common	-31.66	17.78	-31.84	-54.45	-41.31	-47.17
Shares Outstanding (Basic)	7	7	7	6	6	5
Shares Outstanding (Diluted)	7	7	7	6	6	5
Shares Change (YoY)	-	-	6.49%	9.31%	25.69%	25.83%
EPS (Basic)	-4.75	2.67	-4.78	-8.75	-7.34	-10.36
EPS (Diluted)	-4.75	2.67	-4.78	-9.99	-12.00	-10.36
Free Cash Flow	-36.38	-50.48	-52.52	-49.23	-32.67	33.36
Free Cash Flow Per Share	-5.46	-7.58	-7.88	-7.87	-5.71	7.33
Gross Margin	-	75.54%	-0.22%	100.00%	95.95%	90.38%
Operating Margin	-	39.81%	-67.94%	-185.48%	-173.65%	-92.58%
Profit Margin	-	27.23%	-65.22%	-133.80%	-118.73%	-169.96%
Free Cash Flow Margin	-	-77.31%	-107.59%	-120.95%	-93.90%	120.21%
EBITDA	-16.61	26.38	-32.78	-75.16	-60.14	-25.59
EBITDA Margin	-	40.40%	-67.15%	-184.68%	-172.83%	-92.19%
D&A For EBITDA	0.49	0.38	0.39	0.33	0.29	0.11
EBIT	-17.1	26	-33.16	-75.48	-60.42	-25.7
EBIT Margin	-	39.81%	-67.94%	-185.48%	-173.65%	-92.58%
Revenue as Reported	-	65.3	48.82	-	-	-

Updated Mar 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q